| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6884433 | ASTELLAS | Sustained release formulation containing tacrolimus |
Mar, 2019
(5 years ago) | |
| US6576259 | ASTELLAS | Sustained release formulations containing tacrolimus |
Mar, 2019
(5 years ago) | |
| US6440458 | ASTELLAS | Sustained release preparations |
Mar, 2019
(5 years ago) | |
| US8551522 | ASTELLAS | Sustained-release formulation |
Mar, 2019
(5 years ago) | |
Astagraf Xl is owned by Astellas.
Astagraf Xl contains Tacrolimus.
Astagraf Xl has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Astagraf Xl are:
- US6884433
- US6576259
- US6440458
- US8551522
Astagraf Xl was authorised for market use on 19 July, 2013.
Astagraf Xl is available in capsule, extended release;oral dosage forms.
Astagraf Xl can be used as method of once a day administration.
The generics of Astagraf Xl are possible to be released after 24 May, 2025.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | May 24, 2025 |
| New Dosage Form(NDF) | Jul 19, 2016 |
Drugs and Companies using TACROLIMUS ingredient
Market Authorisation Date: 19 July, 2013
Treatment: Method of once a day administration
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
How can I launch a generic of ASTAGRAF XL before it's drug patent expiration?
More Information on Dosage
ASTAGRAF XL family patents
